Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Palatin reported fiscal Q1 2027 revenue of approximately $0.4 million, down sharply from $8.8 million a year ago, with a net loss of $5.1 million ($1.29 per share). The company disclosed substantial doubt about its ability to continue as a going concern, holding just $3.7 million in cash versus $7.5 million at the end of June, and stated additional funding will be required.
Key figures
- Revenue
- 361802
- Guidance
- Phase 1 initiation of lead lipidated MC4R peptide targeted H1 2027; oral small-molecule Phase 1 targeted H2 2027
- Net loss
- 5057511
- Ga expense
- 2080414
- Rd expense
- 3383743
- Cash position
- 3740424
- Mc4r rd spend
- 2100000
- Operating cash use
- 3700000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.